Published in Drug Week, November 11th, 2005
This is the first-ever phase II program for a small interfering RNA (siRNA) therapy, an innovative approach based on the powerful gene silencing technology of RNA interference (RNAi). Acuity also announced the successful results from its phase I study showing that Cand5 appears to be safe and well tolerated.
These phase I results were discussed in three separate presentations at the American Academy of Ophthalmology Annual Meeting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.